{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:16Z","timestamp":1794666136760,"version":"4.9.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Tacrolimus is the most commonly used immunosuppressant drug in solid organ transplant recipients. Different formulations of tacrolimus have distinct pharmacokinetic profiles due to differences in absorption and elimination. This study aimed to investigate the influence of\n                      <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                      polymorphisms on tacrolimus exposure after conversion from immediate-release tacrolimus (Tac-IR) to prolonged-release tacrolimus (Tac-LCP) in stable kidney transplant recipients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Intensive pharmacokinetic sampling was performed in 19 kidney transplant recipients before and 1 month after switching from Tac-IR to Tac-LCP. Patients were genotyped for\n                      <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                      polymorphisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients expressing\n                      <jats:italic toggle=\"yes\">CYP3A5*1<\/jats:italic>\n                      required a significantly higher dose of Tac-IR than nonexpressers to achieve similar predose concentrations (C\n                      <jats:sub>0<\/jats:sub>\n                      ), maximum concentrations (C\n                      <jats:sub>max<\/jats:sub>\n                      ), and area-under-the-curve values (AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      ). After switching to Tac-LCP,\n                      <jats:italic toggle=\"yes\">CYP3A5*1 expressers<\/jats:italic>\n                      had similar C\n                      <jats:sub>0<\/jats:sub>\n                      values but significantly higher C\n                      <jats:sub>max<\/jats:sub>\n                      and AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      values compared with\n                      <jats:italic toggle=\"yes\">nonexpressers<\/jats:italic>\n                      . Dose-normalized exposure showed that\n                      <jats:italic toggle=\"yes\">CYP3A5*1 expressers<\/jats:italic>\n                      had a lower conversion rate than\n                      <jats:italic toggle=\"yes\">nonexpressers<\/jats:italic>\n                      (0.58 versus 0.807).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      These results suggest that CYP3A5 genotype should be considered when adjusting the tacrolimus dose during conversion from Tac-IR to Tac-LCP. C\n                      <jats:sub>0<\/jats:sub>\n                      values may not adequately reflect the higher exposure observed in\n                      <jats:italic toggle=\"yes\">CYP3A5*1 expressers<\/jats:italic>\n                      , highlighting the importance of AUC\n                      <jats:sub>0\u201324<\/jats:sub>\n                      h in guiding dose adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001411","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:00:33Z","timestamp":1765202433000},"page":"463-472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation"],"prefix":"10.1097","volume":"48","author":[{"given":"Anna","family":"Vidal-Alabr\u00f3","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Fontova","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"},{"name":"Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyar","family":"Mohammed Ali","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"},{"name":"Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fern\u00e1ndez-Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Cerezo","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Melilli","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Montero","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coloma","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manonelles","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Fav\u00e0","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Codina","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Couceiro","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Oliveras","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Torras","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Griny\u00f3","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Colom","sequence":"additional","affiliation":[{"name":"Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-5757","authenticated-orcid":false,"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge\u2013IDIBELL, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"R1-20261114","first-page":"S12","article-title":"An overview of immunosuppression in solid organ transplantation","volume":"21","author":"Cher Enderby","year":"2015","journal-title":"Am J Manag Care"},{"key":"R2-20261114","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/01.ju.0000161309.14422.01","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"173","author":"Goldfarb","year":"2005","journal-title":"J Urol"},{"key":"R3-20261114","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1073\/pnas.89.9.3686","article-title":"Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A","volume":"89","author":"Fruman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-20261114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus\u2014personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R6-20261114","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":"Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R7-20261114","doi-asserted-by":"crossref","first-page":"e943498","DOI":"10.12659\/AOT.943498","article-title":"Use of LCP-tacrolimus (LCPT) in kidney transplantation: a Delphi consensus survey of expert clinicians","volume":"29","author":"Wiseman","year":"2024","journal-title":"Ann Transplant"},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am J Transplant"},{"key":"R9-20261114","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2165\/11593890-000000000-00000","article-title":"Once- versus twice-daily tacrolimus: are the formulations truly equivalent?","volume":"71","author":"Barraclough","year":"2011","journal-title":"Drugs"},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplantation"},{"key":"R11-20261114","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/TP.0b013e318296c9d5","article-title":"Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus","volume":"96","author":"Tsuchiya","year":"2013","journal-title":"Transplantation"},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/ajt.12955","article-title":"Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial","volume":"14","author":"Budde","year":"2014","journal-title":"Am J Transplant"},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/TP.0b013e3182962cc1","article-title":"Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients","volume":"96","author":"Gaber","year":"2013","journal-title":"Transplantation"},{"key":"R14-20261114","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1586\/1744666X.2014.983903","article-title":"Once-daily LCP-tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations","volume":"10","author":"Griny\u00f3","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R16-20261114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20261114","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/138920010794328913","article-title":"Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the \u201cadvanced dissolution, absorption, metabolism (ADAM)\u201d model","volume":"11","author":"Darwich","year":"2010","journal-title":"Curr Drug Metab"},{"key":"R18-20261114","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007890-200105150-00021","article-title":"The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients","volume":"71","author":"Tuteja","year":"2001","journal-title":"Transplantation"},{"key":"R19-20261114","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/00912700122009999","article-title":"Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R20-20261114","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/FTD.0000000000000311","article-title":"Effect of breakfast on the exposure of the once-daily tacrolimus formulation in stable kidney transplant recipients","volume":"38","author":"Stifft","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R21-20261114","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin Chem"},{"key":"R22-20261114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R23-20261114","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/j.1600-6143.2006.01518.x","article-title":"CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study","volume":"6","author":"Haufroid","year":"2006","journal-title":"Am J Transplant"},{"key":"R24-20261114","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cpt.2220","article-title":"Sustained inhibition of calcineurin activity with a melt-dose once-daily tacrolimus formulation in renal transplant recipients","volume":"110","author":"Fontova","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20261114","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10337-015-2981-0","article-title":"Simultaneous measurement of cyclosporine A, everolimus, sirolimus and tacrolimus concentrations in human blood by UPLC\u2013MS\/MS","volume":"78","author":"Rigo-Bonnin","year":"2015","journal-title":"Chromatographia"},{"key":"R26-20261114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/tpj.2014.38","article-title":"Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies","volume":"15","author":"Rojas","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"R27-20261114","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FPC.0b013e3282f75f88","article-title":"CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients","volume":"18","author":"Hesselink","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R28-20261114","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.transproceed.2009.01.097","article-title":"Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus","volume":"41","author":"Chen","year":"2009","journal-title":"Transplant Proc"},{"key":"R29-20261114","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.3390\/pharmaceutics15122699","article-title":"CYP3A5*3 and CYP3A4*22 cluster polymorphism effects on LCP-tacrolimus exposure: population pharmacokinetic approach","volume":"15","author":"Mohammed Ali","year":"2023","journal-title":"Pharmaceutics"},{"key":"R30-20261114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FPC.0000000000000494","article-title":"Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation","volume":"33","author":"Rao","year":"2023","journal-title":"Pharmacogenet Genomics"},{"key":"R31-20261114","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5500\/wjt.v13.i6.368","article-title":"Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype","volume":"13","author":"Diamond","year":"2023","journal-title":"World J Transplant"},{"key":"R32-20261114","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1007\/s12325-021-01905-5","article-title":"Therapeutic drug monitoring strategies for envarsus in de novo kidney transplant patients using population modelling and simulations","volume":"38","author":"Henin","year":"2021","journal-title":"Adv Ther"},{"key":"R33-20261114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R34-20261114","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2012.109","article-title":"In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients","volume":"92","author":"de Jonge","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R35-20261114","first-page":"339","article-title":"Improved bioavailability of MeltDose once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hours: a scintigraphic and pharmacokinetic evaluation","volume":"13","author":"Nigro","year":"2013","journal-title":"Am J Transplant"},{"key":"R36-20261114","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","article-title":"Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract","volume":"60","author":"Th\u00f6rn","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R37-20261114","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/ajt.12035","article-title":"Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial","volume":"13","author":"Bunnapradist","year":"2013","journal-title":"Am J Transplant"},{"key":"R38-20261114","doi-asserted-by":"crossref","first-page":"e13767","DOI":"10.1111\/ctr.13767","article-title":"Effectiveness and safety of the conversion to MeltDose\u00ae extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study","volume":"34","author":"S\u00e1nchez Fructuoso","year":"2020","journal-title":"Clin Transplant"},{"key":"R39-20261114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/biomedicines10020272","article-title":"Reducing the pill burden: immunosuppressant adherence and safety after conversion from a twice-daily (IR-Tac) to a novel once-daily (LCP-Tac) tacrolimus formulation in 161 liver transplant patients","volume":"10","author":"Maurer","year":"2022","journal-title":"Biomedicines"},{"key":"R40-20261114","doi-asserted-by":"crossref","first-page":"11366","DOI":"10.3389\/ti.2023.11366","article-title":"Tacrolimus exposure before and after a switch from twice-daily immediate-release to once-daily prolonged release tacrolimus: the ENVARSWITCH study","volume":"36","author":"Monchaud","year":"2023","journal-title":"Transpl Int"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:24Z","timestamp":1794664824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001411","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"2025-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}